Mycobacterium Avium Complex
10
2
3
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
30%
3 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
A Study of Standard Drugs for Mycobacterium Avium Complex
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
Hypertonic Saline Inhalation for Mycobacterium Avium Complex Pulmonary Disease
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
Improving Tolerance of Treatment of Pulmonary MAC Infections